Clovis Oncology Inc of Boulder, Colorado has signalled its confidence in an experimental drug for pancreatic cancer with the signing of a new development and commercialisation deal with the drug’s owner, Clavis Pharma ASA of Norway.
The Austrian vaccine producer, Intercell AG, nearly doubled its loss for the 2010 third quarter, a result that reflected adverse exchange rate movements, a decline in revenue and an increase in spending on late-stage clinical research.
Crucell NV has taken a provision of €22.8 million against its 2010 third-quarter results following the temporary suspension of shipments of two vaccines from a manufacturing facility in Korea that was found to be contaminated.
Schering-Plough Europe has withdrawn its European marketing authorisation application for the proposed asthma treatment, Zenhale (mometasone furoate/formoterol fumarate), the European Medicines Agency announced.
A spin-out from Leicester University in the UK has received institutional and venture capital funding to develop a haemostat, a product that stops bleeding. The project is being supported by the Wellcome Trust.
The Global Alliance for TB Drug Development has launched a clinical trial to test a novel three-drug regime for tuberculosis which, it says, shows promise for treating both drug-sensitive and multidrug-resistant forms of the disease.
Sanofi-Aventis SA has warned the management of Genzyme Corp that its shareholders’ interests could be put in jeopardy if certain defensive measures are put in place to stop Sanofi-Aventis’s bid for the company.
The US Food and Drug Administration has approved Kombiglyze, a new Type 2 diabetes drug that combines saxagliptin and metformin XR in a single tablet, according to the drug’s sponsors, AstraZeneca Plc and Bristol-Myers Squibb Co.
Privately-owned Biocartis SA of Switzerland and bioMerieux of France have entered into a strategic collaboration to co-develop assays for use in a number of healthcare-associated infections, sepsis and oncology.
The US Food and Drug Administration has approved a new indication for Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.